Peptides and tetramers. Comprehensive peptide sets spanning AFP, GPC-3, MAGE-A1 and NY-ESO-1 (18mers overlapping by ten residues; Supplementary Table 1) 
Switzerland) and 0.04 µg/ml anti-CD3 mAb (Immunotech, Marseilles, France) . Twice a week for three weeks, cells were split and supplemented with fresh medium containing IL-2 at a final concentration of 100 U/ml. Experiments were performed no earlier than four days after the last addition of IL-2.
Generation of epitope-specific CD8
+ T-cell lines. CD8 + T-cell lines were generated by plating 4x10 6 PBMC in 1 ml complete medium into one well of a 24-well plate in the presence of 10 µg/ml of the respective peptide and 0.5 µg/ml anti-CD28 mAb (BD). 1 ml complete medium containing recombinant human IL-2 at a final concentration of 20 U/ml was added on days 4 and 11. On day 7, the supernatant was removed and the cells were resuspended in 1 ml complete medium containing 2x10 6 irradiated autologous PBMC and 10 µg/ml of the respective peptide. In some experiments 10 µg/ml anti-PD-L1 mAb (eBioscience, San Diego, CA) or a combination of 10 ng/ml IL-7 (R&D Systems, Minneapolis, MN) and 100 pg/ml IL-12 (PeproTech, Rocky Hill, CT) was added at initiation of cultures. Experiments were performed on day 14 of culture.
Depletion of regulatory T-cells (T reg ). PBMC were labeled with anti-CD25 magnetic beads
and CD25 + cells depleted using a magnetic holder, as described above for CD8 + T-cell isolation. Epitope-specific CD8 + T-cell lines were then generated as described above.
Tetramer-staining. 1x10 6 cells were incubated in one well of a 96-well V-bottom plate (Greiner Bio One) with the respective tetramer in PBS containing 1% fetal bovine serum at 37 °C for 15 min. Subsequently, cells were washed, blocked with pure mouse immunoglobulin G1 (BD), and then surface-stained with phycoerythrin (PE)-labeled anti-CD8 mAb and 7-amino-actinomycin D (ViaProbe; both BD). Finally, cells were fixated in PBS/2%
paraformaldehyde. In some experiments, PE-Cy7-labeled anti-PD-1 and PE-labeled anti-Tim-3 mAbs (both BioLegend, San Diego, CA) were used additionally for surface-staining. In this case, allophycocyanin-H7-labeled anti-CD8 mAb (BD) was used.
Intracellular cytokine staining. For intracellular cytokine staining, cells were incubated for 5 h at 37 °C in one well of a 96-well V-bottom plate in the presence of 50 U/ml recombinant human IL-2 and 1 µg/ml Brefeldin A (BD). Unstimulated wells received no further additions.
For peptide-stimulation, 10 µg/ml of the respective peptide (pools) were added. A combination of 10 ng/ml phorbol-12-myristate-13-acetate and 0.2 µg/ml ionomycin (both Sigma-Aldrich, Seelze, Germany) was used as positive control. Following incubation, cells
were surface-stained with PE-labeled anti-CD8 mAb and ViaProbe and permeabilized using Cytofix/Cytoperm (all BD). Subsequently, the cells were washed with Perm/Wash buffer (BD), stained intracellularly with fluorescein-isothiocyanate-labeled anti-interferon-γ mAb (BD) and fixated with PBS/2% paraformaldehyde. Samples were stored over night at 4 °C prior to flow cytometric acquisition.
Regulatory T-cell (T reg ) staining. PBMC, IHL or TIL were surface stained with peridininchlorophyll-protein-labeled anti-CD4 (BD) and allophycocyanin-labeled anti-CD25
(eBioscience) mAbs. Cells were then permeabilized with the FoxP3/Transcription-FactorStaining-Buffer-Set (eBioscience) and stained with AlexaFluor488-labeled anti-FoxP3 mAb (eBioscience) according to the manufacturer's instructions. Stained samples were analyzed by flow cytometry on the same day after fixation with PBS/2% paraformaldehyde.
Perforin staining. Antigen-specifically expanded cells were stained with tetramer as described above and surface stained with allophycocyanin-H7-labeled anti-CD25, V500-labeled anti-CD8 mAbs and ViaProbe (all BD). Cells were then permeabilized as described for T reg staining and stained with fluorescein-isothiocyanate-labeled anti-Granzyme B, biotin- 
